{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:07:41Z","timestamp":1783429661247,"version":"3.54.6"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40272-023-00592-9","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:03:01Z","timestamp":1697540581000},"page":"9-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Topical Management of Pediatric Psoriasis: A Review of New Developments and Existing Therapies"],"prefix":"10.1007","volume":"26","author":[{"given":"Erina","family":"Lie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Pei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-0474","authenticated-orcid":false,"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"issue":"12","key":"592_CR1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1001\/archderm.143.12.1559","volume":"143","author":"C Huerta","year":"2007","unstructured":"Huerta C, Rivero E, Rodr\u00edguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143(12):1559\u201365.","journal-title":"Arch Dermatol"},{"issue":"1","key":"592_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161\u2013201.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"592_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1365-2133.2009.09593.x","volume":"162","author":"M Augustin","year":"2010","unstructured":"Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Sch\u00e4fer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633\u20136.","journal-title":"Br J Dermatol"},{"issue":"2","key":"592_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/pde.13382","volume":"35","author":"LF Eichenfield","year":"2018","unstructured":"Eichenfield LF, Paller AS, Tom WL, Sugarman J, Hebert AA, Friedlander SF, et al. Pediatric psoriasis: evolving perspectives. Pediatr Dermatol. 2018;35(2):170\u201381.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"592_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1525-1470.2010.01195.x","volume":"27","author":"A Bilgic","year":"2010","unstructured":"Bilgic A, Bilgic \u00d6, Ak\u0131\u015f HK, Eskio\u011flu F, K\u0131l\u0131\u00e7 EZ. Psychiatric symptoms and health-related quality of life in children and adolescents with psoriasis. Pediatr Dermatol. 2010;27(6):614\u20137.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"592_CR6","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/j.1525-1470.2011.01489.x","volume":"28","author":"MEA De Jager","year":"2011","unstructured":"De Jager MEA, De Jong E, Evers AWM, Van De Kerkhof PCM, Seyger MMB. The burden of childhood psoriasis. Pediatr Dermatol. 2011;28(6):736\u20137.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"592_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1442-200X.2006.02270.x","volume":"48","author":"M Seyhan","year":"2006","unstructured":"Seyhan M, Co\u015fkun BK, Sa\u011flam H, Ozcan H, Karincao\u011flu Y. Psoriasis in childhood and adolescence: evaluation of demographic and clinical features. Pediatr Int. 2006;48(6):525\u201330.","journal-title":"Pediatr Int"},{"issue":"11","key":"592_CR8","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1517\/14656566.9.11.2001","volume":"9","author":"JE Frangos","year":"2008","unstructured":"Frangos JE, Kimball AB. Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses. Expert Opin Pharmacother. 2008;9(11):2001\u20137.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"592_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1525-1470.2007.00341.x","volume":"24","author":"A Brune","year":"2007","unstructured":"Brune A, Miller DW, Lin P, Cotrim-Russi D, Paller AS. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol. 2007;24(1):76\u201380.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"592_CR10","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaad.2009.06.048","volume":"62","author":"ME de Jager","year":"2010","unstructured":"de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol. 2010;62(6):1013\u201330.","journal-title":"J Am Acad Dermatol"},{"key":"592_CR11","unstructured":"US FDA. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050777s018lbl.pdf. Accessed 3 Sep 2023."},{"key":"592_CR12","unstructured":"US FDA. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/021302s011lbl.pdf. Accessed 3 Sep 2023."},{"issue":"9","key":"592_CR13","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1111\/jdv.16233","volume":"34","author":"M Seyger","year":"2020","unstructured":"Seyger M, Abramovits W, Liljedahl M, Hoejen MN, Teng J. Safety and efficacy of fixed-dose combination calcipotriol (50\u00a0\u03bcg\/g) and betamethasone dipropionate (0.5\u00a0mg\/g) cutaneous foam in adolescent patients (aged 12 to <17\u00a0years) with plaque psoriasis: results of a phase II, open-label trial. J Eur Acad Dermatol Venereol. 2020;34(9):2026\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"592_CR14","unstructured":"ClinicalTrials.gov. Plaque psoriasis study in pediatric subjects. 2023. https:\/\/clinicaltrials.gov\/study\/NCT02186665. Accessed 1 Aug 2023."},{"issue":"5","key":"592_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1525-1470.2010.01124.x","volume":"27","author":"KR Kortuem","year":"2010","unstructured":"Kortuem KR, Davis MD, Witman PM, McEvoy MT, Farmer SA. Results of Goeckerman treatment for psoriasis in children: a 21-year retrospective review. Pediatr Dermatol. 2010;27(5):518\u201324.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"592_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1525-1470.2008.00774.x","volume":"26","author":"L Borska","year":"2009","unstructured":"Borska L, Andrys C, Krejsek J, Hamakova K, Kremlacek J, Ettler K, et al. Genotoxic hazard and cellular stress in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol. 2009;26(1):23\u20137.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"592_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.mrgentox.2010.01.003","volume":"696","author":"L Borska","year":"2010","unstructured":"Borska L, Smejkalova J, Cerna M, Hamakova K, Kucera I, Kremlacek J, et al. Urinary mutagenicity and genotoxic risk in children with psoriasis after therapeutic exposure to polycyclic aromatic hydrocarbons and ultraviolet radiation. Mutat Res. 2010;696(2):144\u20137.","journal-title":"Mutat Res"},{"issue":"8","key":"592_CR18","doi-asserted-by":"publisher","first-page":"784","DOI":"10.36849\/JDD.2020.5168","volume":"19","author":"B Petersen","year":"2020","unstructured":"Petersen B, Lebwohl M. Treating scalp psoriasis with calcipotriene\/betamethasone dipropionate fixed-dose combination cutaneous foam: review of phase 2 data. J Drugs Dermatol. 2020;19(8):784\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"592_CR19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1046\/j.1365-2133.1996.d01-1010.x","volume":"135","author":"CR Darley","year":"1996","unstructured":"Darley CR, Cunliffe WJ, Green CM, Hutchinson PE, Klaber MR, Downes N. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol. 1996;135(3):390\u20133.","journal-title":"Br J Dermatol"},{"issue":"3","key":"592_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1525-1470.2007.00421.x","volume":"24","author":"L Diluvio","year":"2007","unstructured":"Diluvio L, Campione E, Patern\u00f2 EJ, Mordenti C, El Hachem M, Chimenti S. Childhood nail psoriasis: a useful treatment with tazarotene 0.05%. Pediatr Dermatol. 2007;24(3):332\u20133.","journal-title":"Pediatr Dermatol"},{"key":"592_CR21","unstructured":"ClinicalTrials.gov. A safety and pharmacokinetics study of IDP-118 lotion in pediatric participants with plaque psoriasis. 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03988439. Accessed 1 Jun 2023."},{"issue":"1","key":"592_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jaad.2018.09.002","volume":"80","author":"MG Lebwohl","year":"2019","unstructured":"Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R, et al. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;80(1):282\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"592_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"592_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0149-2918(98)80091-X","volume":"20","author":"J Koo","year":"1998","unstructured":"Koo J, Cuffie CA, Tanner DJ, Bressinck R, Cornell RC, DeVillez RL, et al. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther. 1998;20(2):283\u201391.","journal-title":"Clin Ther"},{"issue":"1","key":"592_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/archderm.141.1.43","volume":"141","author":"CL Carroll","year":"2005","unstructured":"Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol. 2005;141(1):43\u20136.","journal-title":"Arch Dermatol"},{"key":"592_CR26","unstructured":"Arcutis Biotherapeutics. FDA approves Arcutis\u2019 ZORYVE\u2122 (roflumilast) cream 0.3% for the treatment of plaque psoriasis in individuals age 12 and older. 2022. https:\/\/www.arcutis.com\/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older\/. Accessed 25 Apr 2023."},{"key":"592_CR27","first-page":"21","volume":"11","author":"M Milakovic","year":"2021","unstructured":"Milakovic M, Gooderham MJ. Phosphodiesterase-4 inhibition in psoriasis. Psoriasis (Auckl). 2021;11:21\u20139.","journal-title":"Psoriasis (Auckl)."},{"issue":"1","key":"592_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40257-021-00649-w","volume":"23","author":"AM L\u00e9","year":"2022","unstructured":"L\u00e9 AM, Torres T. New topical therapies for psoriasis. Am J Clin Dermatol. 2022;23(1):13\u201324.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"592_CR29","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2022.15632","volume":"328","author":"MG Lebwohl","year":"2022","unstructured":"Lebwohl MG, Kircik LH, Moore AY, Stein-Gold L, Draelos ZD, Gooderham MJ, et al. Effect of roflumilast cream vs. vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA. 2022;328(11):1073\u201384.","journal-title":"JAMA"},{"issue":"8","key":"592_CR30","first-page":"760","volume":"16","author":"H Khosravi","year":"2017","unstructured":"Khosravi H, Siegel MP, Van Voorhees AS, Merola JF. Treatment of inverse\/intertriginous psoriasis: updated guidelines from the Medical Board of the National Psoriasis Foundation. J Drugs Dermatol. 2017;16(8):760\u20136.","journal-title":"J Drugs Dermatol"},{"key":"592_CR31","doi-asserted-by":"crossref","unstructured":"Stein Gold L A-LJ, Draelos ZD, et al. Correlation of itch response to roflumilast cream with disease severity and patient-reported outcomes in patients with chronic plaque psoriasis. In: American Academy of Dermatology Annual Meeting; 2021; Virtual.","DOI":"10.1016\/j.jaad.2021.06.669"},{"issue":"2","key":"592_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40257-022-00741-9","volume":"24","author":"AW Thurston Jr","year":"2023","unstructured":"Thurston AW Jr, Osborne DW, Snyder S, Higham RC, Burnett P, Berk DR. Pharmacokinetics of roflumilast cream in chronic plaque psoriasis: fata from phase I to phase III studies. Am J Clin Dermatol. 2023;24(2):315\u201324.","journal-title":"Am J Clin Dermatol"},{"key":"592_CR33","unstructured":"ClinicalTrials.gov. Safety and efficacy of ARQ-154 foam in adolescent and adult subjects with scalp and body psoriasis. 2022. https:\/\/clinicaltrials.gov\/study\/NCT04128007. Accessed 1 Aug 2023."},{"issue":"1","key":"592_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37\u201349.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"592_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/09546634.2018.1480747","volume":"30","author":"EB Lee","year":"2019","unstructured":"Lee EB, Lebwohl MG, Wu JJ. Treatment of psoriasis with crisaborole. J Dermatolog Treat. 2019;30(2):156\u20137.","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"592_CR36","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1001\/jamadermatol.2018.2397","volume":"154","author":"AB Robbins","year":"2018","unstructured":"Robbins AB, Gor A, Bui MR. Topical crisaborole: a potential treatment for recalcitrant palmoplantar psoriasis. JAMA Dermatol. 2018;154(9):1096\u20137.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"592_CR37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1124\/jpet.116.232819","volume":"358","author":"C Dong","year":"2016","unstructured":"Dong C, Virtucio C, Zemska O, Baltazar G, Zhou Y, Baia D, et al. Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes. J Pharmacol Exp Ther. 2016;358(3):413\u201322.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"592_CR38","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/1744666X.2022.2110071","volume":"18","author":"M Chung","year":"2022","unstructured":"Chung M, Yeroushalmi S, Hakimi M, Bartholomew E, Liao W, Bhutani T. A critical review of halobetasol propionate foam (005%) as a treatment option for adolescent plaque psoriasis. Expert Rev Clin Immunol. 2022;18(10):997\u20131003.","journal-title":"Expert Rev Clin Immunol"},{"key":"592_CR39","unstructured":"ClinicalTrials.gov. Adrenal suppression and absorption study of halobetasol propionate foam in subjects 12-17 with plaque psoriasis. 2022. https:\/\/clinicaltrials.gov\/study\/NCT03992261. Accessed 1 Aug 2023."},{"issue":"1","key":"592_CR40","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40257-021-00641-4","volume":"23","author":"JE Jett","year":"2022","unstructured":"Jett JE, McLaughlin M, Lee MS, Parish LC, DuBois J, Raoof TJ, et al. Tapinarof cream 1% for extensive plaque psoriasis: a maximal use trial on safety, tolerability, and pharmacokinetics. Am J Clin Dermatol. 2022;23(1):83\u201391.","journal-title":"Am J Clin Dermatol"},{"issue":"24","key":"592_CR41","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","volume":"385","author":"MG Lebwohl","year":"2021","unstructured":"Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"4","key":"592_CR42","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","volume":"87","author":"B Strober","year":"2022","unstructured":"Strober B, Stein Gold L, Bissonnette R, Armstrong AW, Kircik L, Tyring SK, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87(4):800\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"592_CR43","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.3390\/ijms21155382","volume":"21","author":"M Furue","year":"2020","unstructured":"Furue M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis. Int J Mol Sci. 2020;21(15):5382.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"592_CR44","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.3390\/ijms20215424","volume":"20","author":"M Furue","year":"2019","unstructured":"Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci. 2019;20(21):5424.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"592_CR45","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","volume":"137","author":"SH Smith","year":"2017","unstructured":"Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110\u20139.","journal-title":"J Invest Dermatol"},{"key":"592_CR46","doi-asserted-by":"crossref","unstructured":"Bagel J, Gold LS, Del Rosso J, Johnson S, Yamauchi P, Brown PM, et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: patient-reported outcomes from the PSOARING 3 trial. J Am Acad Dermatol. 2023. [Epub ahead of print]","DOI":"10.1016\/j.jaad.2023.04.061"},{"issue":"24","key":"592_CR47","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1097\/CM9.0000000000001221","volume":"133","author":"L Cai","year":"2020","unstructured":"Cai L, Chen GH, Lu QJ, Zheng M, Li YZ, Chen J, et al. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J (Engl). 2020;133(24):2905\u20139.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"592_CR48","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/j.jaad.2021.04.103","volume":"85","author":"L Stein Gold","year":"2021","unstructured":"Stein Gold L, Rubenstein DS, Peist K, Jain P, Tallman AM. Tapinarof cream 1% once daily and benvitimod 1% twice daily are 2 distinct topical medications. J Am Acad Dermatol. 2021;85(3):e201\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"592_CR49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjd.12266","volume":"169","author":"WC Ports","year":"2013","unstructured":"Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137\u201345.","journal-title":"Br J Dermatol"},{"issue":"1","key":"592_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","volume":"16","author":"KA Papp","year":"2016","unstructured":"Papp KA, Bissonnette R, Gooderham M, Feldman SR, Iversen L, Soung J, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial. BMC Dermatol. 2016;16(1):15.","journal-title":"BMC Dermatol"},{"issue":"1","key":"592_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/bjd\/ljad098","volume":"189","author":"MN Landis","year":"2023","unstructured":"Landis MN, Smith SR, Berstein G, Fetterly G, Ghosh P, Feng G, et al. Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study. Br J Dermatol. 2023;189(1):33\u201341.","journal-title":"Br J Dermatol"},{"key":"592_CR52","unstructured":"Pfizer Pipeline. 2022. https:\/\/cdn.pfizer.com\/pfizercom\/product-pipeline\/Pipeline_Update_02NOV2021.pdf?xv5ox6MFA62A.LANHa95hryf4ouB.n0s_slide_15. Accessed 3 Sep 2023."},{"key":"592_CR53","unstructured":"ClinicalTrials.gov. A long term study to evaluate the safety and tolerability of CP-690,550 for patients with moderate to severe chronic plaque psoriasis. 2022. https:\/\/clinicaltrials.gov\/study\/NCT01163253. Accessed 1 Aug 2023."},{"key":"592_CR54","unstructured":"Biospace. Sienna Biopharmaceuticals. Files for bankruptcy, delaying phase III psoriasis trial. 2019. https:\/\/www.biospace.com\/article\/sienna-biopharmaceuticals-files-chapter-11-delaying-phase-iii-psoriasis-trial\/. Accessed 3 Sep 2023."},{"key":"592_CR55","unstructured":"Pfizer Pipeline. 2022. https:\/\/cdn.pfizer.com\/pfizercom\/product-pipeline\/Pipeline_Update_02MAY2023_0.pdf?so7sLOHZhv6wg5Nez9aAo9.FrRlGpcRO. Accessed 3 Sep 2023."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00592-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-023-00592-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00592-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T15:16:56Z","timestamp":1704467816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-023-00592-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1007\/s40272-023-00592-9","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"27 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lawrence F. Eichenfield has served as a scientific adviser, consultant, and\/or clinical study investigator for Pfizer Inc., AbbVie, Almirall, Amgen, Asana Biosciences, Cutanea, Dermavant, Dermira, Dr.Reddy\u2019s Laboratory, DS Biopharma, Eli Lilly, Fort\u00e9 Pharma, Galderma, Glenmark, Incyte, LEO Pharma, Matrisys Bioscience, Novan, Novartis, Ortho Dermatologics\/Valeant, Sanofi Regeneron, Sanofi Genzyme, TopMD, UCB, and Verrica. Erina Lie, Mira Choi, and Sheng-Pei Wang have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors made substantial contributions to the conception or design of the work, revised it critically for important intellectual content, approved the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}